Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant
– Putative therapeutic 5-HTP plasma exposures were achieved at all dose levels evaluated – Pharmacodynamic biomarker data demonstrated target engagement, indicative of brain extracellular serotonin elevation beyond the first-line antidepressant effect – The dose range was determined for the planned Phase 2 trial in Major Depressive Disorder patients inadequately responding to first-line antidepressant therapy RESEARCH … [Read more…]
